Angle Is Ready To Capitalize On Promise Of Capture Cell Technology
Angle PLC has published half year interim results which indicate it will capitalize on a new liquid biopsy market.
You may also be interested in...
With approvals looming over the next few months, Angle spoke to Medtech Insight to probe deeper about its presentation at the 2021 Jefferies Healthcare Conference.
The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.
Cognetivity Neuroscience’s CognICA tool uses a language and education-independent approach to assess whether a patient is exhibiting cognitive decline, so it could also aid drug discovery.